Six Hundred Percent of Nothing

The administration's drug pricing claims collapse under basic arithmetic — yet the numbers keep getting bigger. That's not a gaffe. It's a strategy.

By Monexus Staff Writernorth-america4-minute read3 May 2026☆ Save ↗ Share ⎙ Print

"I'm screaming my ass off because the mic is no good." That was Donald Trump on the evening of 1 May 2026, exasperated that the room couldn't hear him. Then he made sure they heard the numbers. "We are delivering discounts with price differences of 600, 700, and sometimes even 800 percent reductions," he told the crowd. The math, as any eighth-grader could explain, does not work.

A reduction from $600 to $10 is not a 600 percent reduction. It is, by the standard formula, roughly a 98 percent reduction. The percentage change equals the amount reduced, divided by the original price. $590 on a $600 base gives 98.3 percent. To get to 600 percent, you would need the reduction itself to exceed the original price six times over. That is not a rounding error. That is a category error.

Robert F. Kennedy Jr. was asked about the figures on 2 May 2026. His defence was not a correction. "President Trump has a different way of calculating percentages," Kennedy said. "If you have a $600 drug and you reduce it to $10, that's a 600% reduction." By that logic, reducing anything to zero would be a 100 percent reduction, and making it free would somehow exceed that. Kennedy was not unaware of the problem. He called it a "different" calculation — which is another way of saying he knew the standard arithmetic didn't apply, and chose to present the distortion as an acceptable alternative framing.

That distinction matters. If this were a simple verbal slip, it would surface in a correction and disappear. When a senior official publicly reframes a basic mathematical error as a valid interpretive option, it functions as a signal to allies: the normal rules do not bind here. The numbers are rhetorical devices. The audience for that signal is not the press corps — it is the people who will repeat the claims in comment sections and on podcasts, who have already decided that fact-checking is itself a form of bias.

This is not the first time the current administration has cited percentage figures that don't survive contact with a calculator. The pattern predates the drug pricing claims. Tariffs get described as "the most beautiful" ever imposed, trade deals as "the greatest" in history. The numbers attached to those claims — the 10 percent, the 25 percent, the phases and pauses and extensions — are real enough. It is the superlatives attached to them that drift into territory where measurement becomes optional. And the media has, by and large, treated those superlatives as a matter of style rather than substance. "He always talks like this" is a description, not a defence.

There is a structural consequence worth spelling out. When the most prominent voice in American government routinely cites figures that do not correspond to reality, it degrades the utility of measurement itself. Price statistics, economic data, health outcome metrics — these are the instruments through which any administration, including this one, is ultimately judged. If those instruments can be casually misrepresented without consequence, then the ability to evaluate actual policy performance erodes. It becomes harder to know whether drug prices have genuinely fallen, whether energy costs have genuinely declined, whether the gap between promise and delivery has narrowed or widened. The people who lose most in that environment are not political opponents — it is anyone trying to make an informed decision about the policies on offer.

The uncomfortable question is why this keeps landing in coverage as a curiosity rather than a correction. The drug pricing claim is not subtle. It is not a disputed methodology or a contested data series. It is basic arithmetic applied to a specific number. A journalist who reported that a company had grown by 600 percent when it had grown by 98 percent would face questions about their competence. When the president does it repeatedly, it becomes a quote in the next day's story, placed alongside a comment from his health secretary and a clip from a congressional hearing, balanced against a sceptical note from a fact-checker that most readers will not click.

The administration knows this. The pattern — make a specific, checkable claim, watch it get amplified without correction, rely on the eventual fact-check landing in fewer eyeballs than the original — is not an accident. It is the same logic behind tariff announcements that outrun the actual implementation details, behind trade deal declarations that predate the text of any agreement, behind a media environment that has learned to treat certainty as a style choice rather than a factual claim.

The drug pricing numbers are, in one sense, an ideal test case: the math is checkable, the stakes are concrete, the primary-source material is unambiguous. The percentage reduction from $600 to $10 is not a contested interpretation. It is a calculation error dressed up as a negotiating triumph. That it keeps circulating as though it were neither is not a failure of arithmetic. It is a failure of the infrastructure that is supposed to correct for it.

Wire provenance

This editorial synthesis draws on the following public wire/social posts:

https://t.me/unusual_whales/2049338571119845376
https://t.me/unusual_whales/2049332143470657536
https://t.me/unusual_whales/2049328796558168064
https://t.me/unusual_whales/2049331418900389888
https://t.me/unusual_whales/2049331418900389888